LOS ANGELES, Dec. 17, 2014 /PRNewswire/ -- ImmunoCellular
Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) announced
that the US Patent and Trademark Office (USPTO) has issued a key
patent covering ImmunoCellular's product candidate ICT-107, a
dendritic cell-based immunotherapeutic vaccine targeting six tumor
antigens that are commonly expressed on glioblastoma. The claims of
US Patent No. 8,871,211, which issued October 28, 2014, include methods of treating
neural cancer by administering a dendritic cell composition
comprising peptide epitopes of the six tumor antigens of
ICT-107. The claims specifically cover administration of the
recited dendritic cell composition to a patient suffering from
glioma, which is inclusive of glioblastoma multiforme.
"This patent provides important protection for ICT-107, and adds
to ImmunoCellular's intellectual property estate for our cancer
vaccine portfolio," said Andrew
Gengos, ImmunoCellular Chief Executive Officer.
The ICT-107 patent was issued to Cedars Sinai Medical Center,
and is exclusively licensed to ImmunoCellular Therapeutics.
About ImmunoCellular Therapeutics, Ltd.
ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that
is developing immune-based therapies for the treatment of brain and
other cancers. ImmunoCellular is conducting a phase II trial of its
lead product candidate, ICT-107, a dendritic cell-based vaccine
targeting multiple tumor-associated antigens for glioblastoma.
ImmunoCellular's pipeline also includes ICT-121, a dendritic cell
vaccine targeting CD133, and ICT-140, a dendritic cell vaccine
targeting ovarian cancer antigens and cancer stem cells. To learn
more about ImmunoCellular, please visit www.imuc.com.
Forward-Looking Statements for ImmunoCellular Therapeutics
This press release contains certain forward-looking statements that
are subject to a number of risks and uncertainties, including the
risk that ICT-107 can be further successfully developed or
commercialized, the status of the current data and whether further
analyses or later studies may confirm the PFS results to date, the
potential for funding and the initiation and design of phase III
trials and possibility of successful results from such studies.
Additional risks and uncertainties are described in IMUC's most
recently filed quarterly report on Form 10-Q and annual report on
Form 10-K. Except as permitted by law, IMUC undertakes no
obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.
In this press release, you can identify forward-looking statements
by terms such as "may," "will," "should," "could," "would,"
"expect," "plan," "anticipate," "believe," "estimate," "project,"
"predict," "potential," "future," "intend," "certain," and similar
expressions intended to identify forward-looking statements.
Contact:
ImmunoCellular Therapeutics, Ltd.
Investor Relations
Jane Green
415.348.0010 direct
415.652.4819 mobile
jane@jmgcomm.com
Logo -
http://photos.prnewswire.com/prnh/20140109/AQ43875LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/immunocellular-therapeutics-announces-issuance-of-key-patent-for-ict-107-cancer-vaccine-300010883.html
SOURCE ImmunoCellular Therapeutics, Ltd.